For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

FLEX by Fenwick is the only service created by an AmLaw 100 firm that provides flexible and cost-effective solutions for interim in-house legal needs to high-growth companies.  MORE >

Fenwick & West handles significant cross-border legal and business issues for a wide range of technology and life sciences who operate internationally..  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked #1 in the Americas for number of technology deals in 2015 by Mergermarket
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney


We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101

New York Office
1211 Avenue of the Americas
32nd Floor
New York, NY 10036

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200

Kevin Kabler, Ph.D.

Associate, Intellectual Property  

San Francisco 415.875.2352


Kevin Kabler focuses his practice on building and managing patent portfolios for companies and institutions in the life sciences industry in the fields of immuno-oncology, antibodies, personalized medicine, vaccines, genetics, biologics, RNAi, stem cells, and immunotherapy. He provides strategic patent counseling and due diligence to his clients at all stages of the business cycle, evaluating risks from third-party patents and assisting in efforts to reduce identified risks, as well as prepares and prosecutes domestic and international patent applications. Kevin also advises investors in assessing the competitive landscape, technology and intellectual property assets and risks associated with target investments.

Kevin has particularly deep technical and legal experience in the fields of immuno-oncology and immunotherapy. Kevin began his hands-on laboratory work in 2002 studying methods of using checkpoint inhibitors within professional antigen presenting cells for use in cancer vaccines. This work resulted in Kevin being a named inventor on multiple patents and a lead author on numerous scientific papers in leading peer-reviewed journals including Nature Medicine and Nature Biotechnology. In his legal career, Kevin has deepened his expertise in immuno-oncology and immunotherapy by counseling leading companies whose technologies range from antibodies to personalized cancer vaccines on the protection and exploitation of their IP and business in the market.

Kevin is also focused on technology that sits at the nexus between traditional biological and medical research and data science. He is a co-founder of a Fenwick working group with Andrew Whitehead that is rapidly iterating on how to improve patents written in this space to successfully navigate the shifting, modern legal landscape that has significantly impacted what subject matter is deemed eligible for patenting.

Kevin began his career at Fenwick & West as a patent agent in 2007. Prior to joining Fenwick & West, Kevin was a postdoctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.

Legal Publications

  • A More Consistent USPTO Approach To Patent Eligibility, Law360, July 2017
  • Shared Routes to Patent Eligibility, Daily Journal, December 2016
  • USPTO Memo Leaves Eligibility Questions Unanswered, Law360, May 2016
  • Divided Infringement Challenges for Personalized Medicine, Daily Journal, June 2015
  • Burdens of Section 101 following Myriad, Daily Journal, October 2013
  • Containing Myriad, The Recorder, August 2013
  • Monoclonal Antibody Patents: Evolving Law & Strategies, Intellectual Property & Technology Law Journal, October 2012

Scientific Publications

  • Human SOCS1 controls immunostimulatory activity of monocyte-derived dendritic cells, Cancer Research, 2009 Oct. 15;69(20):8076-84
  • A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression, Nature Medicine, 2008 Mar.:14(3):258-265
  • Dendritic cell-based tumor vaccines and antigen presentation attenuators, Molecular Therapy, 2006 May;13(5):850-8
  • Inhibition of antigen presentation attenuators to augment vaccines, Current Opinion in Molecular Therapeutics, 2006 Feb.;8(1):24-30
  • SOCS1 restricts dendritic cell's ability to break self-tolerance and induce anti-tumor immunity by controlling IL-12 production and signaling, Journal of Clinical Investigation, 2006 Jan.;116(1):90-100
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells, PLoS Medicine, 2006 Jan.:3(1)e11
  • Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity, Nature Biotechnology, 2004 Dec.;22(12):1546-53